Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.
about
Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonistsThe IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies.Acquired STAT4 deficiency as a consequence of cancer chemotherapy.Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.Impaired development of human Th1 cells in patients with deficient expression of STAT4.Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity.Soypeptide lunasin in cytokine immunotherapy for lymphoma.Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects.Cancer vaccine development: designing tumor cells for greater immunogenicity.Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.
P2860
Q33784491-0CB7ABFB-3B89-43F0-8B99-2BC0B0B4235CQ34327974-194C015C-DAB4-401C-ABF8-539312B1A487Q35604056-3C02AEED-EF0C-4A95-9349-EFBF680E48D4Q37000481-10533AF7-FD4C-4738-A481-A08227251BB1Q37237461-9FFD7E9E-6B1C-491F-B3D5-EC3904A75436Q37416110-FF4BABF8-252D-45AF-B961-8A97DF264382Q37462813-85BF3521-4868-42D2-9BC0-1DC321B12F8CQ37592014-E4A5B3AC-7C3A-4520-B906-02D6C60A8D2EQ37709052-A3A28D42-3A35-443C-A260-F2BA46DC4E67Q37710525-A63E35C8-A7B3-4487-A0A3-FEC9FFB8035AQ42384053-42B429CA-FEEF-4D6C-B038-0219ACA7815CQ42742589-D3BEEF4E-0319-45D0-B507-A7BE5E323B63Q51742964-570009EE-44E5-46F5-BF9C-C692FD9EC30F
P2860
Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Interleukin 12 immunotherapy a ...... or hematological malignancies.
@ast
Interleukin 12 immunotherapy a ...... or hematological malignancies.
@en
type
label
Interleukin 12 immunotherapy a ...... or hematological malignancies.
@ast
Interleukin 12 immunotherapy a ...... or hematological malignancies.
@en
prefLabel
Interleukin 12 immunotherapy a ...... or hematological malignancies.
@ast
Interleukin 12 immunotherapy a ...... or hematological malignancies.
@en
P2093
P1476
Interleukin 12 immunotherapy a ...... for hematological malignancies
@en
P2093
David Pelloso
Kenneth Cornetta
Michael J Robertson
Rafat Abonour
Robert A Hromas
Robert P Nelson
P304
P407
P577
2002-11-01T00:00:00Z